Levadex is filed at the FDA for Migraine - 18-Oct-2012

MAP Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for Levadex orally inhaled migraine drug for the potential acute treatment of migraine in adults.The submission is based on the FREEDOM-301 study see Headache. 2011 Apr;51(4):507-17. doi: 10.1111/j.1526-4610.2011.01869.x. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Aurora SK, Silberstein SD, Kori SH, Tepper SJ, Borland SW, Wang M, Dodick DW. Source; Swedish Headache Center, Seattle, WA, USA. Allergan will co-market the drug in the USA with Botox for migraine.

Related News

Related Neurological Disorders Information

Related Neurological Disorders Drugs

Back to top

Latest News

19 Jun 2013
19 Jun 2013
19 Jun 2013